Denali Therapeutics
DNLI
#3994
Rank
โ‚น259.70 B
Marketcap
โ‚น1,771
Share price
-1.35%
Change (1 day)
-16.21%
Change (1 year)

Revenue for Denali Therapeutics (DNLI)

Revenue in 2025 (TTM): N/A

In 2024 the company made a revenue of N/A a decrease over the revenue in the year 2023 that were of โ‚น27.51 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Denali Therapeutics from 2017 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) N/A
2024 N/A-100%
2023 โ‚น27.51 B206.58%
2022 โ‚น8.97 B147.81%
2021 โ‚น3.62 B-85.25%
2020 โ‚น24.54 B1190.35%
2019 โ‚น1.90 B-78.93%
2018 โ‚น9.03 B
2017 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Novocure
NVCR
โ‚น57.76 BN/A Jersey
Novavax
NVAX
โ‚น92.12 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Organovo
ONVO
โ‚น12.95 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Orchard Therapeutics
ORTX
โ‚น1.96 BN/A๐Ÿ‡ฌ๐Ÿ‡ง UK